Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 67
Filter
1.
Chem Biol Drug Des ; 104(1): e14581, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38997237

ABSTRACT

N-heterocyclic compounds are important molecular scaffolds in the search for new drugs, since most drugs contain heterocyclic moieties in their molecular structure, and some of these classes of heterocycles are able to provide ligands for two or more biological targets. Ketene dithioacetals are important building blocks in organic synthesis and are widely used in the synthesis of N-heterocyclic compounds. In this work, we used double vinylic substitution reactions on ketene dithioacetals to synthesize a small library of heterocyclic derivatives and evaluated their cytotoxic activity in breast and ovarian cancer cells, identifying two benzoxazoles with good potency and selectivity. In silico predictions indicate that the two most active derivatives exhibit physicochemical properties within the range of drug-like compounds and showed potential to interact with HDAC8 and ERK1 cancer-related targets.


Subject(s)
Antineoplastic Agents , Ethylenes , Heterocyclic Compounds , Ketones , Humans , Cell Line, Tumor , Ethylenes/chemistry , Ethylenes/pharmacology , Heterocyclic Compounds/chemistry , Heterocyclic Compounds/pharmacology , Heterocyclic Compounds/chemical synthesis , Antineoplastic Agents/pharmacology , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/chemistry , Ketones/chemistry , Ketones/pharmacology , Ketones/chemical synthesis , Structure-Activity Relationship , Histone Deacetylases/metabolism , Molecular Docking Simulation , Drug Screening Assays, Antitumor , Acetals/chemistry , Acetals/pharmacology , Acetals/chemical synthesis , Repressor Proteins
2.
Bioorg Med Chem ; 107: 117756, 2024 Jun 01.
Article in English | MEDLINE | ID: mdl-38759255

ABSTRACT

Herein, four silver(I) complexes bearing acetylated d-galactopyranoside-based N-heterocyclic carbene ligands were synthesized and fully characterized by elemental analysis, NMR, and X-ray photoelectron spectroscopy. All complexes were obtained with an anomeric ß-configuration and as monocarbene species. In this study, we investigated the biological effects of the silver(I) complexes 2a-d on the human rhabdomyosarcoma cell line, RD. Our results show concentration-dependent effects on cell density, growth inhibition, and activation of key signaling pathways such as Akt 1/2, ERK 1/2, and p38-MAPK, indicating their potential as anticancer agents. Notably, at 35.5 µM, the complexes induced mitochondrial network disruption, as observed with 2b and 2c, whereas with 2a, this disruption was accompanied by nuclear content release. These results provide insight into the utility of carbohydrate incorporated NHC complexes of silver(I) as new agents in cancer therapy.


Subject(s)
Antineoplastic Agents , Cell Proliferation , Drug Screening Assays, Antitumor , Rhabdomyosarcoma , Silver , Humans , Acetylation , Antineoplastic Agents/pharmacology , Antineoplastic Agents/chemistry , Antineoplastic Agents/chemical synthesis , Cell Line, Tumor , Cell Proliferation/drug effects , Coordination Complexes/pharmacology , Coordination Complexes/chemistry , Coordination Complexes/chemical synthesis , Dose-Response Relationship, Drug , Galactose/chemistry , Galactose/pharmacology , Heterocyclic Compounds/chemistry , Heterocyclic Compounds/pharmacology , Heterocyclic Compounds/chemical synthesis , Methane/chemistry , Methane/analogs & derivatives , Methane/pharmacology , Methane/chemical synthesis , Molecular Structure , Rhabdomyosarcoma/drug therapy , Rhabdomyosarcoma/pathology , Silver/chemistry , Silver/pharmacology , Structure-Activity Relationship
3.
Clín. Vet. (São Paulo, Ed. Port.) ; 28(164): 32-42, mai.-jun. 2023. ilus
Article in Portuguese | VETINDEX | ID: biblio-1434773

ABSTRACT

A demodicidose canina é uma dermatopatia parasitária inflamatória comum na rotina clínica. Ela é causada pela proliferação exacerbada do ácaro Demodex spp., e a espécie mais frequentemente encontrada e que causa a doença clínica é o Demodex canis. A doença pode ser classificada conforme a distribuição das lesões e a idade em que elas surgem. Os sinais clínicos mais comuns incluem alopecia, eritema, hiperpigmentação e descamação, e o diagnóstico mais preconizado é o exame parasitológico do raspado cutâneo. Diversos protocolos terapêuticos para a demodicidose canina têm sido estudados, e por muito tempo utilizou-se o amitraz, sendo ao longo dos anos substituído por fármacos da classe das lactonas macrocíclicas, pela praticidade de sua administração. Contudo, mais recentemente, as isoxazolinas (fluralaner, afoxolaner e sarolaner) foram descobertas como miticidas, e nos últimos anos têm demonstrado excelentes resultados. O presente trabalho tem como objetivo realizar uma revisão de literatura sobre as isoxazolinas no tratamento da demodicidose canina.(AU)


Canine demodicosis is an inflammatory parasitic skin disease common in clinical routine. It is caused by the exacerbated proliferation of the Demodex spp., and the most frequently encountered species that causes clinical disease is Demodex canis. The disease can be classified according to the distribution of lesions and the age at which they appear. The most common clinical signs include alopecia, erythema, hyperpigmentation and desquamation, and the most recommended diagnosis is the parasitological examination of the skin scraping. Several therapeutic protocols for canine demodicosis have been studied, and for a long time the main therapeutic of this disease was amitraz, being replaced over the years by drugs of the macrocyclic lactone class due to the practicality of its administration. However, more recently the isoxazolines (fluralaner, afoxolaner and sarolaner) were discovered as miticides, and in recent years they have shown excellent efficacy results, coming to revolutionize the therapy of canine demodicosis. The present study aims to review the literature on isoxazolines in the treatment of canine demodicosis.(AU)


La demodicosis canina es una enfermedad inflamatoria parasitaria de la piel común en la rutina clínica. Es causada por la proliferación exacerbada de Demodex spp., y la especie más frecuente que causa enfermedad clínica es Demodex canis. La enfermedad se puede clasificar según la distribución de las lesiones y la edad en que aparecen. Los signos clínicos más frecuentes incluyen alopecia, eritema, hiperpigmentación y descamación, y el diagnóstico más recomendado es el examen parasitológico del raspado cutáneo. Se han estudiado varios protocolos terapéuticos para la demodicosis canina, y durante mucho tiempo la principal terapéutica de esta enfermedad fue el amitraz, siendo reemplazada con el paso de los años por fármacos de la clase de las lactonas macrocíclicas debido a la practicidad de su administración. Sin embargo, más recientemente se descubrieron las isoxazolinas (fluralaner, afoxolaner y sarolaner) como acaricidas, y en los últimos años han mostrado excelentes resultados de eficacia, llegando a revolucionar la terapia de la demodicosis canina. El presente estudio tiene como objetivo revisar la literatura sobre las isoxazolinas en el tratamiento de la demodicosis canina.(AU)


Subject(s)
Animals , Parasitic Diseases, Animal/drug therapy , Dog Diseases , Heterocyclic Compounds/pharmacology , Mite Infestations/drug therapy , Dogs/parasitology , Mites
4.
J Clin Apher ; 37(3): 245-252, 2022 Jun.
Article in English | MEDLINE | ID: mdl-35114004

ABSTRACT

BACKGROUND: Endothelial progenitor cells (EPCs) are immature cells able to proliferate and contribute to endothelial repair, vascular homeostasis, neovascularization, and angiogenesis. It therefore seems likely that circulating EPCs have therapeutic potential in ischemic and vascular diseases. In this study we evaluated the efficiency of EPC mobilization and collection by large volume leukapheresis in subjects with hematological diseases, treated with plerixafor in association with G-CSF. METHODS: Twenty-two patients with lymphoid malignancies underwent rHuG-CSF and plerixafor treatment followed by leukapheresis. Blood samples before and after treatment and apheresis liquid sample were taken and analyzed by flow cytometry in order to quantified EPC. RESULTS: The percentage of CD34+ cells and EPCs among circulating total nuclear cells (TNCs) increased significantly by approximately 2-fold and 3-fold, respectively, after plerixafor treatment. Consequently, the absolute number of CD34+ cells and EPCs were increased 4-fold after plerixafor treatment. The median PB concentration of EPCs before and after treatment were 0.77/µL (0.31-2.15) and 3.41/µL (1.78-4.54), respectively, P < .0001. The total EPCs collected per patient were 3.3×107 (0.8×107 -6.8×107 ). CONCLUSION: We have shown that plerixafor in combination with G-CSF allows the mobilization and collection of large amounts of EPCs along with CD34+ cells in lymphoid neoplasm patients. The possibility to collect and to store these cells could represent a promising therapeutic tool for the treatment of ischemic complications without the need of in vitro expansion.


Subject(s)
Blood Component Removal , Cyclams , Endothelial Progenitor Cells , Heterocyclic Compounds , Antigens, CD34/metabolism , Benzylamines , Endothelial Progenitor Cells/metabolism , Granulocyte Colony-Stimulating Factor/pharmacology , Granulocyte Colony-Stimulating Factor/therapeutic use , Hematopoietic Stem Cell Mobilization , Heterocyclic Compounds/pharmacology , Heterocyclic Compounds/therapeutic use , Humans
5.
ChemMedChem ; 16(19): 3003-3016, 2021 10 06.
Article in English | MEDLINE | ID: mdl-34231318

ABSTRACT

We prepared a series of free NH and N-substituted dibenzonthiazines with potential anti-tumor activity from N-aryl-benzenesulfonamides. A biological test of synthesized compounds (59 samples) was performed in vitro measuring their antiproliferative activity against a panel of six human solid tumor cell lines and its tubulin inhibitory activity. We identified 6-(phenylsulfonyl)-6H-dibenzo[c,e][1,2]thiazine 5,5-dioxide and 6-tosyl-6H-dibenzo[c,e][1,2]thiazine 5,5-dioxide as the best compounds with promising values of activity (overall range of 2-5.4 µM). Herein, we report the dibenzothiazine core as a novel building block with antiproliferative activity, targeting tubulin dynamics.


Subject(s)
Antineoplastic Agents/pharmacology , Drug Design , Heterocyclic Compounds/pharmacology , Thiazines/pharmacology , Tubulin Modulators/pharmacology , Tubulin/metabolism , Animals , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/chemistry , Brain/drug effects , Brain/metabolism , Cattle , Cell Line, Tumor , Cell Proliferation/drug effects , Cell Survival/drug effects , Dose-Response Relationship, Drug , Drug Screening Assays, Antitumor , Heterocyclic Compounds/chemical synthesis , Heterocyclic Compounds/chemistry , Humans , Molecular Structure , Structure-Activity Relationship , Thiazines/chemistry , Tubulin Modulators/chemical synthesis , Tubulin Modulators/chemistry
6.
J Med Chem ; 64(15): 11418-11431, 2021 08 12.
Article in English | MEDLINE | ID: mdl-34279947

ABSTRACT

DAG-lactones represent useful templates for the design of potent and selective C1 domain ligands for PKC isozymes. The ester moiety at the sn-1 position, a common feature in this template, is relevant for C1 domain interactions, but it represents a labile group susceptible to endogenous esterases. An interesting challenge involves replacing the ester group of these ligands while still maintaining biological activity. Here, we present the synthesis and functional characterization of novel diacylglycerol-lactones containing heterocyclic ring substituents at the sn-1 position. Our results showed that the new compound 10B12, a DAG-lactone with an isoxazole ring, binds PKCα and PKCε with nanomolar affinity. Remarkably, 10B12 displays preferential selectivity for PKCε translocation in cells and induces a PKCε-dependent reorganization of the actin cytoskeleton into peripheral ruffles in lung cancer cells. We conclude that introducing a stable isoxazole ring as an ester surrogate in DAG-lactones emerges as a novel structural approach to achieve PKC isozyme selectivity.


Subject(s)
Diglycerides/pharmacology , Drug Design , Heterocyclic Compounds/pharmacology , Lactones/pharmacology , Protein Kinase C/metabolism , Diglycerides/chemical synthesis , Diglycerides/chemistry , Dose-Response Relationship, Drug , HeLa Cells , Heterocyclic Compounds/chemical synthesis , Heterocyclic Compounds/chemistry , Humans , Isoenzymes/metabolism , Lactones/chemical synthesis , Lactones/chemistry , Molecular Structure , Structure-Activity Relationship
7.
Expert Rev Clin Pharmacol ; 14(6): 677-686, 2021 Jun.
Article in English | MEDLINE | ID: mdl-33843400

ABSTRACT

INTRODUCTION: Nonsteroidal anti-inflammatory drugs (NSAIDs) are a class of drugs widely used due to their pharmacological potential, demonstrating anti-inflammatory, analgesic, or antipyretic activity. However, prolonged use of these medications can lead to the development of gastric ulcers in patients. This review aimed to find patents for drugs with an anti-inflammatory and gastroprotective character to treat NSAID-induced gastric ulcers. AREAS COVERED: For the treatment of NSAID-induced gastric ulcers, formulations with different action mechanisms were found, including donors of nitric oxide, heterocyclic compounds, and natural products. EXPERT OPINION: Many of the structures found have already been used in clinic settings and others, and according to the results found, they are promising for the treatment of gastric ulcers.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Anti-Ulcer Agents/administration & dosage , Stomach Ulcer/prevention & control , Animals , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Anti-Ulcer Agents/pharmacology , Biological Products/administration & dosage , Biological Products/pharmacology , Heterocyclic Compounds/administration & dosage , Heterocyclic Compounds/pharmacology , Humans , Nitric Oxide Donors/administration & dosage , Nitric Oxide Donors/pharmacology , Patents as Topic , Stomach Ulcer/chemically induced
8.
Mol Divers ; 25(1): 55-66, 2021 Feb.
Article in English | MEDLINE | ID: mdl-31900682

ABSTRACT

Cancer is one of the leading causes of death worldwide and requires intense and growing research investments from the public and private sectors. This is expected to lead to the development of new medicines. A determining factor in this process is the structural understanding of molecules with potential anticancer properties. Since the major compounds used in cancer therapies fail to encompass every spectrum of this disease, there is a clear need to research new molecules for this purpose. As it follows, we have studied the class of quinolinones that seem effective for such therapy. This paper describes the structural elucidation of a novel dihydroquinoline by single-crystal X-ray diffraction and spectroscopy characterization. Topology studies were carried through Hirshfeld surfaces analysis and molecular electrostatic potential map; electronic stability was evaluated from the calculated energy of frontier molecular orbitals. Additionally, in silico studies by molecular docking indicated that this dihydroquinoline could act as an anticancer agent due to their higher binding affinity with human aldehyde dehydrogenase 1A1 (ALDH 1A1). Tests in vitro were performed for VERO (normal human skin keratinocytes), B16F10 (mouse melanoma), and MDA-MB-231 (metastatic breast adenocarcinoma), and the results certified that compound as a potential anticancer agent. A Dihydroquinoline derivative was tested against three cancer cell lines and the results attest that compound as potential anticancer agent.


Subject(s)
Antineoplastic Agents/chemistry , Antineoplastic Agents/pharmacology , Neoplasms/drug therapy , Quinolines/chemistry , Quinolines/pharmacology , Animals , Cell Line , Cell Line, Tumor , Cell Proliferation/drug effects , Chlorocebus aethiops , Crystallography, X-Ray/methods , Drug Screening Assays, Antitumor/methods , Heterocyclic Compounds/chemistry , Heterocyclic Compounds/pharmacology , Humans , Mice , Models, Molecular , Molecular Docking Simulation/methods , Quinolones/chemistry , Quinolones/pharmacology , Structure-Activity Relationship , Vero Cells
9.
J Biomed Mater Res B Appl Biomater ; 109(8): 1105-1115, 2021 08.
Article in English | MEDLINE | ID: mdl-33283412

ABSTRACT

Gadolinium-based contrast agents (CAs) were synthesized using faujasite zeolite (NaX) and zeolite beta (BEA) and their performances in vitro and in vivo were compared to the widely used commercial CA, gadoteric acid (Gd-DOTA). Magnetic resonance imaging (MRI) relaxometry studies (considering longitudinal [T1 ] and transverse [T2 ] relaxation times) were performed using Gd-DOTA and the zeolitic materials loaded with Gd3+ . The Gd-loaded NaX, which presented large pores and cavities (7.35 and 11.24 Å, respectively), exhibited relaxivity values of around 52 mM-1 s-1 , while BEA, which presented smaller pore and cavity diameters (5.95 and 6.68 Å, respectively) showed lower relaxivity values of ~4.8 mM-1 s-1 . The effect of the Gd-loaded NaX as MRI CA was tested in vivo in Sprague-Dawley rats, employing a 7 T scanner, with comparison to Gd-DOTA MRI angiography. The relaxivity measurements showed that the Gd-loaded NaX (50 mM-1 s-1 ) provided better image contrast than Gd-DOTA (5.1 mM-1 s-1 ). Clearance studies of the CAs using urine and blood showed that both Gd-loaded NaX and Gd-DOTA were eliminated from the body after 2 days, demonstrating the potential of Gd-loaded NaX for use as an MRI CA.


Subject(s)
Contrast Media , Gadolinium , Heterocyclic Compounds , Magnetic Resonance Imaging , Organometallic Compounds , Zeolites , Animals , Contrast Media/chemistry , Contrast Media/pharmacokinetics , Contrast Media/pharmacology , Female , Gadolinium/chemistry , Gadolinium/pharmacokinetics , Gadolinium/pharmacology , Heterocyclic Compounds/chemistry , Heterocyclic Compounds/pharmacokinetics , Heterocyclic Compounds/pharmacology , Organometallic Compounds/chemistry , Organometallic Compounds/pharmacokinetics , Organometallic Compounds/pharmacology , Rats , Rats, Sprague-Dawley , Zeolites/chemistry , Zeolites/pharmacokinetics , Zeolites/pharmacology
10.
Molecules ; 25(24)2020 Dec 13.
Article in English | MEDLINE | ID: mdl-33322179

ABSTRACT

The selenophene derivatives are an important class of selenium-based heterocyclics. These compounds play an important role in prospecting new drugs, as well as in the development of new light-emitting materials. During the last years, several methods have been emerging to access the selenophene scaffold, employing a diversity of cyclization-based synthetic strategies, involving specific reaction partners and particularities. This review presents a comprehensive discussion on the recent advances in the synthesis of selenophene-based compounds, starting from different precursors, highlighting the main differences, the advantages, and limitations among them.


Subject(s)
Chemistry Techniques, Synthetic , Heterocyclic Compounds/chemical synthesis , Organoselenium Compounds/chemical synthesis , Chemistry Techniques, Synthetic/methods , Chemistry Techniques, Synthetic/trends , Cyclization , Heterocyclic Compounds/chemistry , Heterocyclic Compounds/pharmacology , Molecular Structure , Organoselenium Compounds/chemistry , Organoselenium Compounds/pharmacology
11.
Bioorg Med Chem Lett ; 30(20): 127491, 2020 10 15.
Article in English | MEDLINE | ID: mdl-32795626

ABSTRACT

A series of synthetic 1,2,4-trioxanes related to artemisinin was tested against L. donovani and T. cruzi parasites. This screening identified some active compounds, with key common structural features. Interestingly, these selected trioxanes were efficient against both parasites, and achieved antiparasitic activities comparable or superior than those presented by the corresponding reference drugs, artemisinin and artesunate. This study represents the first example of synthetic trioxanes evaluated on T. cruzi and provides possible candidates for developing new drugs for the treatment of leishmaniasis and Chagas disease.


Subject(s)
Antiparasitic Agents/pharmacology , Heterocyclic Compounds/pharmacology , Leishmania donovani/drug effects , Trypanosoma cruzi/drug effects , Antiparasitic Agents/chemical synthesis , Antiparasitic Agents/chemistry , Dose-Response Relationship, Drug , Heterocyclic Compounds/chemical synthesis , Heterocyclic Compounds/chemistry , Molecular Structure , Parasitic Sensitivity Tests , Structure-Activity Relationship
12.
Food Chem ; 322: 126725, 2020 Aug 30.
Article in English | MEDLINE | ID: mdl-32283373

ABSTRACT

The antimutagenicity of an extract from the medicinal plant Asclepias subulata (ASE) against heterocyclic aromatic amines (HAAs) commonly found in cooked meat, as well as its stability to heat treatment (HT), was evaluated. HT (180 °C/3 min) had no effect on the content in ASE of the bioactive compound corotoxigenin-3-O-glucopyranoside; conversely, calotropin significantly decreased by 72%. ASE exerted antimutagenicity against PhIP, MelQ, and MelQx in TA98 and TA100 Salmonella strains, and this activity was not affected by heat, with the exception of MelQ (p < 0.05). Since HAAs can induce colorectal cancer, the thermal stability of ASE's antiproliferative effect against colorectal cancer cells was also evaluated. HT decreased (p < 0.05) the antiproliferative activity of ASE; however, the remaining activity was still strong with an IC50 of 16.8 ± 2.03 µg/mL. Therefore, ASE can be used as a food ingredient to reduce the carcinogenic potential of thermally induced HAAs.


Subject(s)
Amines/pharmacology , Antimutagenic Agents/pharmacology , Asclepias/chemistry , Carcinogens/pharmacology , Heterocyclic Compounds/pharmacology , Meat/analysis , Plant Extracts/chemistry , Plant Extracts/pharmacology , Amines/analysis , Amines/chemistry , Animals , Antimutagenic Agents/chemistry , Carcinogens/chemistry , Cell Proliferation/drug effects , Cooking , Heterocyclic Compounds/analysis , Hot Temperature , Humans , Imidazoles
13.
Pharmacol Rep ; 72(1): 47-54, 2020 Feb.
Article in English | MEDLINE | ID: mdl-32016848

ABSTRACT

BACKGROUND: Diabetic neuropathy is a common cause of painful diabetic neuropathy (PDN). C-X-C chemokine receptor type 4 (CXCR4) expression is increased in peripheral nerve samples from diabetes patients, suggesting a role for CXCR4 in PDN. Therefore, we evaluated the effects of Phα1ß, ω-conotoxin MVIIA, and AMD3100 in a model of streptozotocin (STZ)-induced PDN in rodents and naïve model of rats with the activation of the CXCR4/stromal cell-derived factor 1 (SDF-1) signal. METHODS: Diabetic neuropathy was induced by intraperitoneal (ip) injection of STZ in Wistar rats. Naïve rats were intrathecally injected with SDF-1 to test the CXCR4/SDF-1 signal. The effects of Phα1ß intrathecal (it), ω-conotoxin MVIIA intrathecal (it), and AMD3100 intraperitoneal (ip) on rat hypersensitivity, IL-6, and the intracellular calcium [Ca2+]i content of diabetic synaptosomes were studied. RESULTS: The drugs reduced the hypersensitivity in diabetic rats. SDF-1 (1.0 µg/it) administration in naïve rats induced hypersensitivity. Phα1ß (100 pmol/it) or AMD3100 (2.5 µg/ip) reduced this hypersensitivity after 2 h treatments, while ω-conotoxin MVIIA did not have an effect. IL-6 and [Ca2+]i content increased in the spinal cord synaptosomes in diabetic rats. The drug treatments reduced IL-6 and the calcium influx in diabetic synaptosomes. CONCLUSIONS: Phα1ß, ω-conotoxin MVIIA, and AMD3100, after 2 h of treatment of STZ-induced PDN, reduced hypersensitivity in diabetic rats. In naïve rats with CXCR4/SDF-1 activation, the induced hypersensitivity decreased after 2 h treatments with Phα1ß or AMD-3100, while ω-conotoxin MVIIA did not affect. The inhibitory effects of Phα1ß on PDN may involve voltage-dependent calcium channels.


Subject(s)
Analgesics/pharmacology , Diabetes Mellitus, Experimental/drug therapy , Diabetic Neuropathies/drug therapy , Spider Venoms/pharmacology , Animals , Benzylamines , Calcium/metabolism , Calcium Channels/metabolism , Chemokine CXCL12/metabolism , Cyclams , Diabetes Mellitus, Experimental/complications , Heterocyclic Compounds/pharmacology , Rats , Rats, Wistar , Receptors, CXCR4/metabolism , omega-Conotoxins/pharmacology
14.
Cells ; 9(2)2020 02 11.
Article in English | MEDLINE | ID: mdl-32053908

ABSTRACT

The mitochondrion has emerged as a promising therapeutic target for novel cancer treatments because of its essential role in tumorigenesis and resistance to chemotherapy. Previously, we described a natural compound, 10-((2,5-dihydroxybenzoyl)oxy)decyl) triphenylphosphonium bromide (GA-TPP+C10), with a hydroquinone scaffold that selectively targets the mitochondria of breast cancer (BC) cells by binding to the triphenylphosphonium group as a chemical chaperone; however, the mechanism of action remains unclear. In this work, we showed that GA-TPP+C10 causes time-dependent complex inhibition of the mitochondrial bioenergetics of BC cells, characterized by (1) an initial phase of mitochondrial uptake with an uncoupling effect of oxidative phosphorylation, as previously reported, (2) inhibition of Complex I-dependent respiration, and (3) a late phase of mitochondrial accumulation with inhibition of α-ketoglutarate dehydrogenase complex (αKGDHC) activity. These events led to cell cycle arrest in the G1 phase and cell death at 24 and 48 h of exposure, and the cells were rescued by the addition of the cell-penetrating metabolic intermediates l-aspartic acid ß-methyl ester (mAsp) and dimethyl α-ketoglutarate (dm-KG). In addition, this unexpected blocking of mitochondrial function triggered metabolic remodeling toward glycolysis, AMPK activation, increased expression of proliferator-activated receptor gamma coactivator 1-alpha (pgc1α) and electron transport chain (ETC) component-related genes encoded by mitochondrial DNA and downregulation of the uncoupling proteins ucp3 and ucp4, suggesting an AMPK-dependent prosurvival adaptive response in cancer cells. Consistent with this finding, we showed that inhibition of mitochondrial translation with doxycycline, a broad-spectrum antibiotic that inhibits the 28 S subunit of the mitochondrial ribosome, in the presence of GA-TPP+C10 significantly reduces the mt-CO1 and VDAC protein levels and the FCCP-stimulated maximal electron flux and promotes selective and synergistic cytotoxic effects on BC cells at 24 h of treatment. Based on our results, we propose that this combined strategy based on blockage of the adaptive response induced by mitochondrial bioenergetic inhibition may have therapeutic relevance in BC.


Subject(s)
Antineoplastic Agents/pharmacology , Breast Neoplasms/drug therapy , Mitochondria/drug effects , Protein Biosynthesis/drug effects , AMP-Activated Protein Kinase Kinases , Apoptosis/drug effects , Breast Neoplasms/genetics , Breast Neoplasms/pathology , Cell Proliferation/drug effects , Doxycycline/pharmacology , Drug Synergism , Female , Gentisates/chemistry , Gentisates/pharmacology , Heterocyclic Compounds/chemistry , Heterocyclic Compounds/pharmacology , Humans , Ketoglutarate Dehydrogenase Complex/antagonists & inhibitors , Ketoglutarate Dehydrogenase Complex/genetics , Mitochondria/pathology , Organophosphorus Compounds/chemistry , Organophosphorus Compounds/pharmacology , Oxidative Phosphorylation/drug effects , Protein Kinases/genetics , Ribosomes/drug effects
15.
Curr Med Chem ; 26(36): 6544-6563, 2019.
Article in English | MEDLINE | ID: mdl-30378479

ABSTRACT

Bromodomains recognize and bind acetyl-lysine residues present in histone and non-histone proteins in a specific manner. In the last decade they have raised as attractive targets for drug discovery because the miss-regulation of human bromodomains was discovered to be involved in the development of a large spectrum of diseases. However, targeting eukaryotic pathogens bromodomains continues to be almost unexplored. We and others have reported the essentiality of diverse bromodomain- containing proteins in protozoa, offering a new opportunity for the development of antiparasitic drugs, especially for Trypansoma cruzi, the causative agent of Chagas' disease. Mammalian bromodomains were classified in eight groups based on sequence similarity but parasitic bromodomains are very divergent proteins and are hard to assign them to any of these groups, suggesting that selective inhibitors can be obtained. In this review, we describe the importance of lysine acetylation and bromodomains in T. cruzi as well as the current knowledge on mammalian bromodomains. Also, we summarize the myriad of small-molecules under study to treat different pathologies and which of them have been tested in trypanosomatids and other protozoa. All the information available led us to propose that T. cruzi bromodomains should be considered as important potential targets and the search for smallmolecules to inhibit them should be empowered.


Subject(s)
Chagas Disease/drug therapy , Protozoan Proteins/antagonists & inhibitors , Trypanocidal Agents/pharmacology , Acetylation , Animals , Cell Line, Tumor , Heterocyclic Compounds/pharmacology , Heterocyclic Compounds/therapeutic use , Humans , Lysine/chemistry , Protein Domains/drug effects , Protein Processing, Post-Translational , Protozoan Proteins/chemistry , Trypanocidal Agents/therapeutic use , Trypanosoma cruzi/drug effects
17.
Bioorg Med Chem ; 26(17): 4850-4862, 2018 09 15.
Article in English | MEDLINE | ID: mdl-30173929

ABSTRACT

Despite the impressive scientific and technological advances of recent decades, no effective treatment is currently available for Chagas disease. Our research group has been studying the design and synthesis of analogues of natural lignans aiming to identify compounds with antiparasitic activity. This article reports the synthesis of 42 novel bis-heterocyclic derivatives and the structure-activity relationship study conducted based on results of biological assays against Trypanosoma cruzi amastigotes. Thirty-seven compounds were active, and eight of them had GI50 values lower than 100 µM (GI50 88.4-12.2 µM). A qualitative structure activity relationship study using three dimensional descriptors was carried out and showed a correlation between growth inhibitory potency and the presence of bulky hydrophobic groups located at rings A and D of the compounds. Compound 3-(3,4-dimethoxyphenyl)-5-((4-(4-pentylphenyl)-1H-1,2,3-triazol-1-yl)methyl)isoxazole (31) was the most active in the series (GI50 12.2 µM), showing, in vitro, low toxicity and potency similar to benznidazole (GI50 10.2 µM). These results suggest that this compound can be a promising scaffold for the design of new trypanocidal compounds.


Subject(s)
Antiprotozoal Agents/chemical synthesis , Antiprotozoal Agents/pharmacology , Leishmania/drug effects , Lignans/chemistry , Trypanosoma cruzi/drug effects , Antiprotozoal Agents/chemistry , Carbon-13 Magnetic Resonance Spectroscopy , Drug Evaluation, Preclinical , Heterocyclic Compounds/chemical synthesis , Heterocyclic Compounds/chemistry , Heterocyclic Compounds/pharmacology , Humans , Isoxazoles/chemical synthesis , Isoxazoles/chemistry , Isoxazoles/pharmacology , NADH, NADPH Oxidoreductases/antagonists & inhibitors , Proton Magnetic Resonance Spectroscopy , Spectrophotometry, Infrared , Structure-Activity Relationship , THP-1 Cells , Triazoles/chemical synthesis , Triazoles/chemistry , Triazoles/pharmacology
18.
Molecules ; 23(5)2018 05 09.
Article in English | MEDLINE | ID: mdl-29747438

ABSTRACT

γ-Aminobutyric acid (GABA) is the most important inhibitory neurotransmitter in the central nervous system, and a deficiency of GABA is associated with serious neurological disorders. Due to its low lipophilicity, there has been an intensive search for new molecules with increased lipophilicity to cross the blood-brain barrier to raise GABA concentrations. We have designed and evaluated in vitro and in silico some new analogues of GABA, where the nitrogen atom at the γ-position is embedded in heterocyclic scaffolds and determined their inhibitory potential over the GABA-AT enzyme from Pseudomonas fluorescens. These modifications lead to compounds with inhibitory activity as it occurs with compounds 18a and 19a. The construction of Pseudomonas fluorescens and human GABA-AT models were carried out by homology modeling. Docking assays were done for these compounds over the GABA-AT enzyme models where 19a showed a strong interaction with both GABA-AT enzymes.


Subject(s)
4-Aminobutyrate Transaminase/antagonists & inhibitors , Computer Simulation , Heterocyclic Compounds/chemistry , Heterocyclic Compounds/pharmacology , Models, Molecular , Pseudomonas fluorescens/enzymology , gamma-Aminobutyric Acid/analogs & derivatives , Catalytic Domain , Enzyme Inhibitors/chemical synthesis , Enzyme Inhibitors/chemistry , Enzyme Inhibitors/pharmacology , Heterocyclic Compounds/chemical synthesis , Humans , Hydrogen Bonding , Molecular Docking Simulation , Static Electricity
19.
Eur J Med Chem ; 143: 21-32, 2018 Jan 01.
Article in English | MEDLINE | ID: mdl-29172080

ABSTRACT

Herein we report the straightforward preparation of novel conformationally-restricted steroids from trans-androsterone and estrone, decorated with spiranic oxazolidin-2-one or 2-aminooxazoline motifs at C-17 as potential antiproliferative agents. Such unprecedented pharmacophores were accessed using an aminomethylalcohol derivative at C-17 as the key intermediate; reaction of such functionality with triphosgene, or conversion into N-substituted thioureas, followed by an intramolecular cyclodesulfurization reaction promoted by yellow HgO, furnished such spirocycles in excellent yields. Title compounds were tested in vitro against a panel of six human tumor cell lines, named A549 (non-small cell lung), HBL-100 (breast), HeLa (cervix), SW1573 (non-small cell lung), T-47D (breast) and WiDr (colon), and the results were compared with steroidal chemotherapeutic agents (abiraterone and galeterone); the A-ring of the steroidal backbone, the nature of the heterocycle and the N-substituents proved to be essential motifs for establishing structure-activity relationships concerning not only the potency but also the selectivity against tumor cell lines. Estrone derivatives, particularly those bearing a spiranic 2-aminooxazoline scaffold were found to be the most active compounds, with GI50 values ranging from the low micromolar to the submicromolar level (0.34-1.5 µM). Noteworthy, the lead compounds showed a remarkable increase in activity against the resistant cancer cell lines (T-47D and WiDr) compared to the anticancer reference drugs (up to 120-fold).


Subject(s)
Antineoplastic Agents/pharmacology , Heterocyclic Compounds/pharmacology , Spiro Compounds/pharmacology , Steroids/pharmacology , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/chemistry , Cell Line, Tumor , Cell Proliferation/drug effects , Crystallography, X-Ray , Dose-Response Relationship, Drug , Drug Screening Assays, Antitumor , Heterocyclic Compounds/chemical synthesis , Heterocyclic Compounds/chemistry , Humans , Models, Molecular , Molecular Structure , Spiro Compounds/chemical synthesis , Spiro Compounds/chemistry , Steroids/chemical synthesis , Steroids/chemistry , Structure-Activity Relationship
20.
J Med Chem ; 60(20): 8647-8660, 2017 10 26.
Article in English | MEDLINE | ID: mdl-28968083

ABSTRACT

Tuberculosis, caused by Mycobacterium tuberculosis (Mtb), is the infectious disease responsible for the highest number of deaths worldwide. Herein, 22 new N-oxide-containing compounds were synthesized followed by in vitro and in vivo evaluation of their antitubercular potential against Mtb. Compound 8 was found to be the most promising compound, with MIC90 values of 1.10 and 6.62 µM against active and nonreplicating Mtb, respectively. Additionally, we carried out in vivo experiments to confirm the safety and efficacy of compound 8; the compound was found to be orally bioavailable and highly effective, leading to a reduction of Mtb to undetectable levels in a mouse model of infection. Microarray-based initial studies on the mechanism of action suggest that compound 8 blocks translation. Altogether, these results indicate that benzofuroxan derivative 8 is a promising lead compound for the development of a novel chemical class of antitubercular drugs.


Subject(s)
Antitubercular Agents/chemistry , Antitubercular Agents/pharmacology , Heterocyclic Compounds/chemistry , Heterocyclic Compounds/pharmacology , Animals , Antitubercular Agents/chemical synthesis , Antitubercular Agents/pharmacokinetics , Biological Availability , Caco-2 Cells , Heterocyclic Compounds/chemical synthesis , Heterocyclic Compounds/pharmacokinetics , Humans , Mice , Mice, Inbred BALB C , Microbial Sensitivity Tests , Mycobacterium tuberculosis/drug effects , Oxides/chemistry , Spectrum Analysis/methods
SELECTION OF CITATIONS
SEARCH DETAIL